Actively Recruiting
Phase 1 Study of TT-01488 Oral Tablets for Adults With B-Cell Cancers to Assess Safety and Dose Levels
Led by TransThera Sciences (Nanjing), Inc. · Updated on 2023-11-21
37
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and early effectiveness of TT-01488, an oral tablet that reversibly inhibits BTK, in adults with B-cell malignancies who have not responded to or tolerated previous treatments. This open-label Phase I study aims to find a suitable dose for further testing and to assess how the drug behaves in the body. The study is sponsored by TransThera Sciences Nanjing, Inc. The trial has two parts a dose escalation phase where TT-01488 tablets are given once daily in 28-day cycles at increasing doses to find the recommended dose for expansion followed by a dose expansion phase where this dose is further tested for safety and early effectiveness. The dose escalation uses a modified 33 design starting at 50 mg daily, with the goal of identifying a recommended Phase II dose based on safety, drug levels, and response. Participants will take daily tablets and undergo assessments including monitoring for dose-limiting toxicities within 28 days of the first dose, along with safety and response evaluations over three years. Researchers will track adverse events, drug concentration in the blood, and measures like disease control and survival. The study is non-randomized and open-label, and participant involvement may last up to three years depending on outcomes and follow-up needs.
CONDITIONS
Brief Title
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
Research Team
S
Sun Caixia, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here